{"id":"https://openalex.org/W2262017487","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7050","title":"Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).","display_name":"Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2262017487","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7050","mag":"2262017487"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.7050","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7050","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7050","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048380048","display_name":"John Victor Heymach","orcid":"https://orcid.org/0000-0001-9068-8942","observed_orcids":["https://orcid.org/0000-0001-9068-8942"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Heymach","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967559","display_name":"Bonnie S. Glisson","orcid":"https://orcid.org/0009-0006-7320-2940","observed_orcids":["https://orcid.org/0009-0006-7320-2940"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. S. Glisson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034705456","display_name":"Robert Charles Doebele","orcid":"https://orcid.org/0000-0001-6728-6857","observed_orcids":["https://orcid.org/0000-0001-6728-6857"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. C. Doebele","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001077325","display_name":"Chongbiao Huang","orcid":"https://orcid.org/0000-0001-9468-9168","observed_orcids":["https://orcid.org/0000-0001-9468-9168"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Huang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036091074","display_name":"David R. Gandara","orcid":"https://orcid.org/0000-0003-1784-048X","observed_orcids":["https://orcid.org/0000-0003-1784-048X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. R. Gandara","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070356700","display_name":"Stephanie Le Scouiller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Le Scouiller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108414513","display_name":"Marcelo Marotti","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. A. Marotti","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5082517668","display_name":"D. Ross Camidge","orcid":"https://orcid.org/0000-0003-3430-3213","observed_orcids":["https://orcid.org/0000-0003-3430-3213"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. R. Camidge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"7050","last_page":"7050"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.005900000222027302,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.968999981880188},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":1.0},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/vegf-inhibitors","display_name":"VEGF inhibitors","score":0.7749999761581421},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8149999976158142},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6610000133514404},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7960000038146973},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9520000219345093},{"id":"https://openalex.org/keywords/metastatic-lung-cancer","display_name":"metastatic lung cancer","score":0.7110000252723694},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.38999998569488525},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8949999809265137},{"id":"https://openalex.org/keywords/hemoptysis","display_name":"hemoptysis","score":0.9290000200271606},{"id":"https://openalex.org/keywords/recist-response","display_name":"RECIST response","score":0.5680000185966492},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.48100000619888306},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.46399998664855957}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9349561333656311},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6971498131752014},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6754124164581299},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.546505331993103},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5452693700790405},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5434148907661438},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5083116888999939},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.47148773074150085},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4420490860939026},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3587057590484619},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.35554957389831543},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32463693618774414}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.7050","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7050","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7050","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8500000238418579,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4402115543","https://openalex.org/W2078797757","https://openalex.org/W2245201628","https://openalex.org/W2109240520","https://openalex.org/W2024760455","https://openalex.org/W2152376701","https://openalex.org/W2527842292","https://openalex.org/W2255387339","https://openalex.org/W2070907611","https://openalex.org/W4237929233"],"abstract_inverted_index":{"7050":[0],"Background:":[1],"Cediranib":[2,336],"is":[3,341,358,368,376],"an":[4,118,247],"oral,":[5],"highly":[6],"potent":[7],"inhibitor":[8],"of":[9,40,58,79,93,226,284,348],"VEGF":[10],"signaling":[11],"with":[12,52,165,361,370],"additional":[13,114],"activity":[14,349],"versus":[15],"c-":[16],"Kit.":[17],"This":[18],"study":[19],"assessed":[20],"cediranib":[21,54,80,172,213,269,372],"plus":[22],"EP":[23,41,176,217,340,362],"as":[24],"first-line":[25],"therapy":[26],"for":[27,69,201],"extensive":[28],"stage/metastatic":[29],"lung":[30,353],"cancer.":[31],"Methods:":[32],"Pts":[33],"received":[34,143,280],"up":[35],"to":[36,117,146,171,246],"six":[37],"21-day":[38],"cycles":[39],"(E":[42],"100":[43],"mg/m2,":[44,49],"days":[45,78],"1\u20133;":[46],"P":[47],"80":[48],"day":[50,56],"1)":[51],"once-daily":[53],"from":[55,316],"4":[57,154],"cycle":[59],"1":[60,236],"until":[61],"disease":[62],"progression":[63],"or":[64,81,230,381,385],"toxicity":[65,86],"and":[66,95,112,222,232,260,277,328,344,352],"were":[67,218,238,267],"eligible":[68],"safety":[70,94],"review":[71],"if":[72],"they":[73],"completed":[74],"the":[75,107,147,162,187,281,308,312],"first":[76],"21":[77],"had":[82,142,332],"a":[83,102,105,193,287,297,333],"dose":[84,108,164,270,274,283],"limiting":[85],"(DLT).":[87],"The":[88,167,224,365],"primary":[89],"objective":[90],"was":[91,109,151,198,321,325],"assessment":[92,290],"tolerability.":[96],"If":[97],"<":[98],"33%":[99],"pts":[100,115,128,155,185,211,242,279,295,331],"in":[101,186,208,318,350],"cohort":[103,150,191,202],"experienced":[104,192],"DLT":[106,194],"deemed":[110],"tolerable":[111],"12":[113],"recruited":[116],"expanded":[119],"cohort.":[120],"Results:":[121],"At":[122],"data":[123],"cut-off":[124],"(Aug":[125],"09),":[126],"22":[127],"(50%":[129],"male;":[130],"mean":[131,313],"age":[132],"60":[133],"years;":[134],"SCLC/NEC":[135],"histology":[136],"82%/18%;":[137],"WHO":[138],"PS":[139],"0/1/2":[140],"14%/77%/9%)":[141],"treatment.":[144],"Recruitment":[145],"30":[148,304],"mg":[149,160,174,190,215,305,310,338],"stopped":[152],"at":[153],"(all":[156,228,255],"SCLC)":[157],"when":[158],"20":[159,173,189,214,309,337],"became":[161],"recommended":[163],"chemotherapy.":[166],"following":[168],"results":[169],"relate":[170],"+":[175,216,339],"(n":[177,234,262],"=":[178,235,257,263],"18,":[179],"14/4":[180],"SCLC/NEC).":[181],"As":[182],"only":[183],"1/6":[184],"initial":[188],"(hemoptysis),":[195],"this":[196],"combination":[197],"considered":[199],"suitable":[200],"expansion.":[203],"Adverse":[204],"events":[205],"(AEs)":[206],"reported":[207],"\u2265":[209],"50%":[210],"receiving":[212],"nausea,":[219],"vomiting,":[220],"neutropenia":[221],"diarrhea.":[223],"incidences":[225],"hypertension":[227],"G1":[229],"2)":[231],"fatigue":[233],"G3)":[237,259],"both":[239],"39%.":[240],"Five":[241],"discontinued":[243],"treatment":[244],"due":[245],"AE:":[248],"anemia,":[249],"duodenal":[250],"ulcer":[251],"bleeding,":[252],"increased":[253],"creatinine":[254],"n":[256],"1,":[258],"hemoptysis":[261],"2,":[264],"G3).":[265],"There":[266],"no":[268],"reductions":[271],"(mean":[272],"daily":[273],"18.5":[275],"mg)":[276],"all":[278],"planned":[282],"EP.":[285],"In":[286,307],"preliminary":[288],"efficacy":[289],"(RECIST),":[291],"10/14":[292],"(71%)":[293],"SCLC":[294,351],"achieved":[296],"partial":[298],"response":[299],"(PR)":[300],"(12/18":[301],"[67%]":[302],"including":[303],"cohort).":[306],"cohort,":[311],"best":[314],"change":[315],"baseline":[317],"tumor":[319],"size":[320],"-53.3%.":[322],"Median":[323],"PFS":[324,357],"8":[326],"months":[327],"5/8":[329],"ongoing":[330],"PR.":[334],"Conclusions:":[335],"well":[342],"tolerated":[343],"has":[345],"shown":[346],"evidence":[347],"NEC.":[354],"Preliminary":[355],"median":[356],"favorable":[359],"compared":[360],"historical":[363],"data.":[364],"AE":[366],"profile":[367],"consistent":[369],"previous":[371],"studies.":[373],"Further":[374],"investigation":[375],"warranted.":[377],"Author":[378],"Disclosure":[379],"Employment":[380],"Leadership":[382],"Position":[383],"Consultant":[384],"Advisory":[386],"Role":[387],"Stock":[388],"Ownership":[389],"Honoraria":[390],"Research":[391],"Funding":[392],"Expert":[393],"Testimony":[394],"Other":[395],"Remuneration":[396],"AstraZeneca,":[397,401,418],"Response":[398],"Genetics":[399],"Amgen,":[400],"Biodesix,":[402],"Bristol-Myers":[403,419],"Squibb/ImClone,":[404,420],"Boehringer":[405],"Ingelheim,":[406],"Genentech,":[407,421],"GlaxoSmithKline,":[408],"Lilly,":[409,422],"Merck,":[410,423],"Novartis,":[411,424],"Pfizer,":[412],"sanofi-aventis":[413],"AstraZeneca":[414,415],"Abbott":[416],"Laboratories,":[417],"Pfizer":[425]},"counts_by_year":[{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}